J.W. Cole Advisors’s AbCellera Biologics ABCL Stock Holding History

J.W. Cole Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.27M	Buy	+86,825	New	+$824K	0.02%	659

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

J.W. Cole Advisors's ABCL Position: Q3 2026 in Review

J.W. Cole Advisors opened a new position in AbCellera Biologics (ABCL) in Q3 2026: 86,825 shares worth $1.27M. The stake represents 0.02% of the portfolio and ranks #659 among its holdings.

49 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

J.W. Cole Advisors held 86,825 shares of AbCellera Biologics worth $1.27M as of Q3 2026.
AbCellera Biologics was a new J.W. Cole Advisors position in Q3 2026.
AbCellera Biologics made up 0.02% of J.W. Cole Advisors's portfolio in Q3 2026, its #659 holding.
49 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on J.W. Cole Advisors's 13F filing for Q3 2026, filed 5 Nov 2026.